Promacta — CareFirst (Caremark)

Initial criteria

• Member is prescribed the requested drug for the initiation and maintenance of interferon-based therapy for treatment of thrombocytopenia associated with chronic hepatitis C

Reauthorization criteria

• Authorization of 6 months may be granted to members continuing interferon-based therapy

Approval duration

initial 12 months; continuation 6 months